Bayer CEO Threatens US Glyphosate Halt as Legal Drag Intensifies
Published on 06/05/2026 at 22:13 | Redaktion boerse-global.de
The German pharmaceutical and agriculture giant finds itself in a deepening strategic bind. On one side, operating performance is improving; on the other, legal liabilities continue to devour cash and dominate the narrative. Chief Executive Bill Anderson has now escalated the conflict by warning of a complete halt to glyphosate production in the United States unless a durable legal solution is reached. With over 100,000 Roundup lawsuits still pending, the threat is not empty — a production stop would hit American farming hard and underscore how legacy litigation is bleeding into core operations.
The stock itself is treading water at a critical technical juncture. In Frankfurt trading, shares edged up 1.36 percent to €35.82, hovering practically on the 200-day moving average of €35.80. On a monthly view, the stock is still down 7.01 percent, while year-to-date losses stand at roughly 5.80 percent. The secondary article reported a slightly higher level of €36.12 with a 2 percent daily gain, reflecting intraday volatility. Market capitalisation sits at about €33.5 billion.
Operationally, the first quarter of 2026 offered real encouragement. Net profit rose to €2.76 billion, and the Crop Science division posted currency-adjusted sales growth of 6.8 percent, supported by lucrative licensing deals and a robust performance in Consumer Health. Earnings per share comfortably beat expectations. Yet the cash flow statement tells a more troubling story: free cash flow came in at minus €2.32 billion, largely due to roughly €2 billion in settlement payments linked to PCB and glyphosate claims. Analysts see potential for EBITDA to surpass €10 billion by 2028, but that scenario depends on a credible easing of legal costs — something that remains elusive.
Should investors sell immediately? Or is it worth buying Bayer?
The legal calendar is dense and fraught with risk. By end of June, a landmark decision from the US Supreme Court on glyphosate pre-emption is expected. Should Bayer prevail, it could pave the way for a comprehensive resolution. Then, in July, a fairness hearing for the $7.25 billion Roundup class-action settlement is scheduled. In parallel, plaintiff lawyers are trying to move cases from Missouri to a federal court in California known for being hostile to Bayer. Management is fighting that move in court while Anderson pressures Washington.
A new front has also opened in the agricultural business. Reports emerged of fresh lawsuits linked to genetically modified corn seed, adding another layer of legal exposure at a time when the company is trying to shift investor focus away from litigation and toward operational strength. mwb research maintains a price target of €52.00, arguing that recent legal headlines are sentiment-driven and the current share price already embeds a high risk discount.
Major shareholders are running out of patience. Union Investment has voiced sharp frustration, demanding margins rather than visions. The call for returns over rhetoric reflects a growing unease across the shareholder base. Yet Bayer’s management continues to rule out a spin-off of the Monsanto agriculture unit, insisting it will resolve the legal knots within the current structure — even as it says it is keeping all options open.
The conflict between improved fundamentals and unrelenting legal overhang keeps the stock pinned near its long-term moving average. A clean break above €35.80 would brighten the chart, while a failure risks confirming the recent rally as a mere bear-market bounce. Until the Supreme Court rules or the July settlement hearing clarifies the path, Bayer remains caught between a robust operational engine and a legal drag that shows no sign of letting up.
Ad
Bayer Stock: New Analysis - 5 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
